ALK-abello A/S Class B ( (AKBLF) ) has released its Q4 earnings. Here is a breakdown of the information ALK-abello A/S Class B presented to its investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ALK-Abelló A/S is a global specialty pharmaceutical company based in Denmark, focused on developing and marketing allergy immunotherapy treatments and other allergy-related products. The company reported a 15% increase in sales for 2024, with profits rising by 65%, marking the best results in its history. Key financial metrics showed a revenue of DKK 5,537 million and an EBIT of DKK 1,091 million, with a strong performance particularly in Europe. The company achieved major milestones, including the approval of a pediatric house dust mite tablet and a licensing agreement for an adrenaline nasal spray. Looking ahead, ALK expects revenue growth of 9-13% in 2025 with continued emphasis on expanding its tablet sales across various regions and improving its EBIT margin to around 25% through strategic optimizations and revenue growth.